Who are Placebo、5-Fluorouracil、Leucovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Irinotecan, 5FU, leucovorin, Capecitabine (Xeloda®), Unitrim.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-5-fluorouracil-leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo、5-Fluorouracil、Leucovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo、5-Fluorouracil、Leucovorin (Placebo、5-Fluorouracil、Leucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy. Area: Oncology.

phase 3 Antimetabolite chemotherapy Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo、5-Fluorouracil、Leucovorin (Placebo、5-Fluorouracil、Leucovorin) — Jiangsu HengRui Medicine Co., Ltd.. 5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo、5-Fluorouracil、Leucovorin TARGET	Placebo、5-Fluorouracil、Leucovorin	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Antimetabolite chemotherapy	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Capecitabine (Xeloda®)	Capecitabine (Xeloda®)	National Cancer Center, Korea	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Unitrim	BRODIMOPRIM		marketed	brodimoprim	Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy class)

Hoffmann-La Roche · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo、5-Fluorouracil、Leucovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-5-fluorouracil-leucovorin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab